• Jaguar Health expanded compassionate-use access to its oral crofelemer formulation for an infant with intestinal failure linked to congenital sodium diarrhea.
• Clinical results were already presented in June 2026 from ongoing pediatric investigations in microvillus inclusion disease, short bowel syndrome with intestinal failure.
• Those studies indicated patients reduced reliance on parenteral support over long-term dosing, with tolerability described as favorable.
• A randomized double-blind phase in a pivotal pediatric microvillus inclusion disease trial has been completed, with data expected to support regulatory discussions.
• An NDA filing for crofelemer in microvillus inclusion disease is targeted for mid-2027, with a potential Breakthrough Therapy request beforehand.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609040830ACCESSWRNAPR_____1216539) on September 04, 2026, and is solely responsible for the information contained therein.